Results 51 to 60 of about 19,992 (185)
The emerging role of the first 17 amino acids of huntingtin in Huntington’s disease
Biomolecular Concepts, 2015 Huntington’s disease (HD) is caused by a polyglutamine (polyQ) domain that is expanded beyond a critical threshold near the N-terminus of the huntingtin (htt) protein, directly leading to htt aggregation. While full-length htt is a large (on the order of
Arndt James R. +2 more
doaj +1 more source
Presynaptic APP levels and synaptic homeostasis are regulated by Akt phosphorylation of huntingtin
eLife, 2020 Studies have suggested that amyloid precursor protein (APP) regulates synaptic homeostasis, but the evidence has not been consistent. In particular, signaling pathways controlling APP transport to the synapse in axons and dendrites remain to be ...
Julie Bruyère +12 more
doaj +1 more source
Polyglutamine Repeat Length-Dependent Proteolysis of Huntingtin
Neurobiology of Disease, 2002 Amino-terminal fragments of huntingtin, which contain the expanded polyglutamine repeat, have been proposed to contribute to the pathology of Huntington's disease (HD).
Banghua Sun +20 more
doaj +1 more source
Health Care Science, EarlyView.This review elucidates the crosstalk between Parkinson's disease and colorectal cancer, driven by shared genetics (PRKN, PINK1, DJ‐1) involving oxidative stress, cell cycle regulation, and inflammation. It identifies the gut microbiota—via functional amyloids and short‐chain fatty acids (SCFAs)—as a mechanistic bridge, offering insights for dual ...
Jiacheng Ying +6 more
wiley +1 more source
PLoS ONE, 2014 A hallmark of Huntington's disease is the pronounced sensitivity of striatal neurons to polyglutamine-expanded huntingtin expression. Here we show that cultured striatal cells and murine brain striatum have remarkably low levels of phosphorylation of ...
Julia Leitman +6 more
doaj +1 more source
Systematic Review of the Huntington's Disease Drug Development Pipeline, 2014 to 2025
Movement Disorders, EarlyView.Abstract Background In the past decade, significant advances have improved our understanding of the mechanisms underlying HD pathobiology leading to several putative therapeutic targets for HD. Objective The aim was to describe the Huntington's disease (HD) drug development clinical pipeline.
Pavlina Konstantinova +5 more
wiley +1 more source
Movement Disorders, EarlyView.Abstract Background Although not confirmed, some studies have suggested that elevated homocysteine levels are common in patients with Huntington's disease (HD). Its clinical relevance remains unclear. Objectives We aimed to assess vitamin B and homocysteine levels in HD patients and explore the relationships among hyperhomocysteinemia, vitamin B ...
Salomé Puisieux +16 more
wiley +1 more source
Angewandte Chemie, Volume 138, Issue 33, 10 August 2026.In this review, we discuss how biomolecular condensates can inhibit amyloid aggregation in their interior, while still facilitating fibril formation at the interface between the dense and dilute phases, where molecular and mesoscale properties are likely optimal to promote protein aggregation.
Marcell Papp +3 more
wiley +2 more sources
The Predicted Structure of the Headpiece of the Huntingtin Protein and Its Implications on Huntingtin Aggregation [PDF]
Journal of Molecular Biology, 2009 We have performed simulated tempering molecular dynamics simulations to study the thermodynamics of the headpiece of the Huntingtin (Htt) protein (N17(Htt)). With converged sampling, we found this peptide is highly helical, as previously proposed. Interestingly, this peptide is also found to adopt two different and seemingly stable states.
Kelley, Nicholas W. +5 more
openaire +3 more sources
Molecular Brain, 2009 Background Huntington's disease (HD) is an inherited neurogenerative disease caused by an abnormal expansion of glutamine repeats in the huntingtin protein.
Pineda Jose R +5 more
doaj +1 more source